Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kyle Holen

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|April 21, 2006
Therapeutic and palliative options for diffuse neuroendocrine metastatic diseaseKyle Holen
Clinical Colorectal Cancer|June 8, 2007
Treatment with panitumumab after a severe infusion reaction to cetuximab in a patient with metastatic colorectal cancer: a case reportJames Heun, Kyle Holen
Molecular Cancer Therapeutics|June 16, 2005
ZM336372, a Raf-1 activator, suppresses growth and neuroendocrine hormone levels in carcinoid tumor cellsJamie J Van Gompel, Muthusamy Kunnimalaiyaan, Kyle Holen, et al.
The Oncologist|December 19, 2008
Carcinoid tumorsScott N Pinchot, Kyle Holen, Rebecca S Sippel, et al.
The Journal of Surgical Research|December 25, 2009
ZM336372 induces apoptosis associated with phosphorylation of GSK-3beta in pancreatic adenocarcinoma cell linesDustin Deming, Peter Geiger, Herbert Chen, et al.
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|February 27, 2008
ZM336372, a Raf-1 activator, causes suppression of proliferation in a human hepatocellular carcinoma cell lineDustin Deming, Peter Geiger, Herbert Chen, et al.
Investigational New Drugs|October 10, 2007
The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitorKyle Holen, Leonard B Saltz, Ellen Hollywood, et al.
Anticancer Research|April 3, 2014
Effect of co-administration of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics, safety and tolerability of navitoclax, a first-in-class oral Bcl-2 family inhibitor, in cancer patientsAhmed Hamed Salem, Jianning Yang, Alison Graham, et al.
Cancer Chemotherapy and Pharmacology|May 5, 2010
Population pharmacokinetics of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (Triapine®) in cancer patientsJill Kolesar, Richard C Brundage, Marcia Pomplun, et al.
Archives of Surgery (Chicago, Ill. : 1960)|October 18, 2006
Metastatic neuroendocrine hepatic tumors: resection improves survivalSandeepa Musunuru, Herbert Chen, Sharad Rajpal, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|April 21, 2006
Therapeutic and palliative options for diffuse neuroendocrine metastatic diseaseKyle Holen
Clinical Colorectal Cancer|June 8, 2007
Treatment with panitumumab after a severe infusion reaction to cetuximab in a patient with metastatic colorectal cancer: a case reportJames Heun, Kyle Holen
Molecular Cancer Therapeutics|June 16, 2005
ZM336372, a Raf-1 activator, suppresses growth and neuroendocrine hormone levels in carcinoid tumor cellsJamie J Van Gompel, Muthusamy Kunnimalaiyaan, Kyle Holen, et al.
The Oncologist|December 19, 2008
Carcinoid tumorsScott N Pinchot, Kyle Holen, Rebecca S Sippel, et al.
The Journal of Surgical Research|December 25, 2009
ZM336372 induces apoptosis associated with phosphorylation of GSK-3beta in pancreatic adenocarcinoma cell linesDustin Deming, Peter Geiger, Herbert Chen, et al.
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|February 27, 2008
ZM336372, a Raf-1 activator, causes suppression of proliferation in a human hepatocellular carcinoma cell lineDustin Deming, Peter Geiger, Herbert Chen, et al.
Investigational New Drugs|October 10, 2007
The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitorKyle Holen, Leonard B Saltz, Ellen Hollywood, et al.
Anticancer Research|April 3, 2014
Effect of co-administration of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics, safety and tolerability of navitoclax, a first-in-class oral Bcl-2 family inhibitor, in cancer patientsAhmed Hamed Salem, Jianning Yang, Alison Graham, et al.
Cancer Chemotherapy and Pharmacology|May 5, 2010
Population pharmacokinetics of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (Triapine®) in cancer patientsJill Kolesar, Richard C Brundage, Marcia Pomplun, et al.
Archives of Surgery (Chicago, Ill. : 1960)|October 18, 2006
Metastatic neuroendocrine hepatic tumors: resection improves survivalSandeepa Musunuru, Herbert Chen, Sharad Rajpal, et al.
Pageof 2